Mainz Biomed N.V. (QUCY)

$0.74 -0.02 (-2.77%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 275,300
Avg Vol 630,766
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 30%
Beta N/A
Analysts Hold
Price Target N/A
tr53
tr53 Mar. 20 at 3:37 PM
$QUCY Mynz -Qucy-junk
0 · Reply
Genesys01
Genesys01 Mar. 20 at 11:02 AM
$QUCY no the most dead thing ever is RDHL, an Israel Biotech which is generating reverse splits like a machine gun. But yes, MYNZ/QUCY is going into the same direction.
0 · Reply
HJAC
HJAC Mar. 19 at 5:56 PM
$QUCY WTF is this company doing? I thought their Pancreatic CA test sounded great!
1 · Reply
JHisai
JHisai Mar. 19 at 11:22 AM
$QUCY for those who care to do their DD: there is precedence, something in common and a pattern at Indaptus Therapeutics INDP, Cyclacel Pharmaceuticals CYCC, KALA Bio KALA, NovaBay Pharmaceuticals NBY, Sow Good Inc. SOWG
0 · Reply
JHisai
JHisai Mar. 19 at 10:43 AM
$QUCY AI says 1) What happened Mainz Biomed N.V. rebranded in March 2026 to “Quantum Cyber” (QUCY), replaced leadership with a cybersecurity-focused chairman, and began exiting or winding down its biotech operations. This represents a full strategic break, not a gradual transition. 2) Financial condition before the shift The company operated with extremely low revenue and very high losses over multiple years. Margins were deeply negative and liquidity constrained, indicating a business that was not economically viable in its existing form. 3) Dilution and funding pattern The company relied heavily on repeated capital raises to survive. These financings included structures that led to continuous shareholder dilution. Over time, this resulted in a significant increase in share count and persistent downward pressure on the stock. tbc, see comments
2 · Reply
Spacerobot
Spacerobot Mar. 18 at 11:42 PM
$QUCY THis beast is in the news, and is this low? Seems like an easy toss for something.
0 · Reply
theflynews
theflynews Mar. 18 at 2:16 PM
Trump Trade: President issues short-term waiver of Jones Act - $QUCY - https://thefly.com/QUCY
0 · Reply
KOWALSK1
KOWALSK1 Mar. 18 at 8:32 AM
$QUCY ✅️ BUY ZONE 0.56 to 0.54 ✋️ RISK BELOW 0.10 💲PT. 0.63 0.77 0.84 0.92+ + UP Follow for more
0 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Mar. 17 at 3:34 PM
$QUCY HOLY SHIT THIS IS THE MOST DEAD THING EVER!!!!! DOWN 95%
0 · Reply
twixbarrtwits
twixbarrtwits Mar. 17 at 3:31 PM
$QUCY the 2nd 3 million placement was executed today
1 · Reply
Latest News on QUCY
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY

Mar 13, 2026, 7:30 AM EDT - 8 days ago

Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

Mar 11, 2026, 7:30 AM EDT - 10 days ago

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Jan 14, 2026, 9:15 AM EST - 2 months ago

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Nov 18, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Nov 12, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Nov 10, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Oct 8, 2025, 9:00 AM EDT - 5 months ago

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Sep 2, 2025, 8:01 AM EDT - 7 months ago

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 13, 2025, 8:01 AM EDT - 7 months ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Aug 4, 2025, 10:22 AM EDT - 8 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 23, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jul 15, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 25, 2025, 8:01 AM EDT - 9 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Jun 10, 2025, 9:01 AM EDT - 10 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 19, 2025, 8:01 PM EDT - 10 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

May 16, 2025, 8:01 AM EDT - 11 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 29, 2025, 8:01 AM EDT - 11 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Apr 28, 2025, 8:01 AM EDT - 11 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 27, 2025, 9:01 AM EDT - 1 year ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 13, 2025, 8:01 AM EDT - 1 year ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mar 3, 2025, 8:01 AM EST - 1 year ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed Expands into Switzerland with labor team w

Feb 20, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Feb 11, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 27, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Jan 21, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 19, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 16, 2024, 5:00 PM EST - 1 year ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 12, 2024, 8:00 PM EST - 1 year ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Dec 3, 2024, 2:40 PM EST - 1 year ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Mainz Biomed Announces Stock Split

Nov 29, 2024, 8:45 AM EST - 1 year ago

Mainz Biomed Announces Stock Split

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Oct 1, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Mainz Biomed Provides Half Year 2024 Corporate Update

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

May 7, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 25, 2024, 9:29 AM EDT - 2 years ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Mainz Biomed Reports Full Year 2023 Financial Results

Apr 9, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 19, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 18, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 12, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mar 5, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 27, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

tr53
tr53 Mar. 20 at 3:37 PM
$QUCY Mynz -Qucy-junk
0 · Reply
Genesys01
Genesys01 Mar. 20 at 11:02 AM
$QUCY no the most dead thing ever is RDHL, an Israel Biotech which is generating reverse splits like a machine gun. But yes, MYNZ/QUCY is going into the same direction.
0 · Reply
HJAC
HJAC Mar. 19 at 5:56 PM
$QUCY WTF is this company doing? I thought their Pancreatic CA test sounded great!
1 · Reply
JHisai
JHisai Mar. 19 at 11:22 AM
$QUCY for those who care to do their DD: there is precedence, something in common and a pattern at Indaptus Therapeutics INDP, Cyclacel Pharmaceuticals CYCC, KALA Bio KALA, NovaBay Pharmaceuticals NBY, Sow Good Inc. SOWG
0 · Reply
JHisai
JHisai Mar. 19 at 10:43 AM
$QUCY AI says 1) What happened Mainz Biomed N.V. rebranded in March 2026 to “Quantum Cyber” (QUCY), replaced leadership with a cybersecurity-focused chairman, and began exiting or winding down its biotech operations. This represents a full strategic break, not a gradual transition. 2) Financial condition before the shift The company operated with extremely low revenue and very high losses over multiple years. Margins were deeply negative and liquidity constrained, indicating a business that was not economically viable in its existing form. 3) Dilution and funding pattern The company relied heavily on repeated capital raises to survive. These financings included structures that led to continuous shareholder dilution. Over time, this resulted in a significant increase in share count and persistent downward pressure on the stock. tbc, see comments
2 · Reply
Spacerobot
Spacerobot Mar. 18 at 11:42 PM
$QUCY THis beast is in the news, and is this low? Seems like an easy toss for something.
0 · Reply
theflynews
theflynews Mar. 18 at 2:16 PM
Trump Trade: President issues short-term waiver of Jones Act - $QUCY - https://thefly.com/QUCY
0 · Reply
KOWALSK1
KOWALSK1 Mar. 18 at 8:32 AM
$QUCY ✅️ BUY ZONE 0.56 to 0.54 ✋️ RISK BELOW 0.10 💲PT. 0.63 0.77 0.84 0.92+ + UP Follow for more
0 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Mar. 17 at 3:34 PM
$QUCY HOLY SHIT THIS IS THE MOST DEAD THING EVER!!!!! DOWN 95%
0 · Reply
twixbarrtwits
twixbarrtwits Mar. 17 at 3:31 PM
$QUCY the 2nd 3 million placement was executed today
1 · Reply
tr53
tr53 Mar. 17 at 3:15 PM
$QUCY Being messed with again
0 · Reply
MoneyWind_9804
MoneyWind_9804 Mar. 17 at 3:12 PM
$QUCY looks interesting
0 · Reply
samprice792
samprice792 Mar. 17 at 3:12 PM
$QUCY WHY NOT?
0 · Reply
tr53
tr53 Mar. 17 at 3:11 PM
$QUCY New ticker symbol - but same shit
0 · Reply
zerotrust07
zerotrust07 Mar. 17 at 3:01 PM
$QUCY what happened to all the other messages from like 3 years back. This is such a scam
0 · Reply
Makethatmoneyson
Makethatmoneyson Mar. 17 at 1:37 PM
$QUCY
1 · Reply
RealSituation
RealSituation Mar. 11 at 12:04 PM
$QUCY What a shame
0 · Reply
Steffen986
Steffen986 Aug. 16 at 1:47 PM
$QUCY good news today.
0 · Reply
minime2022
minime2022 Aug. 16 at 1:44 PM
$QUCY we need more watchers and traders on this stock - almost unknown
0 · Reply
MakingDreamsReality
MakingDreamsReality Aug. 16 at 12:09 PM
PM mOOvers 👀 $AMTD - AMTD IDEA Group to Inject US$500 Million Worth of Global Portfolio of Premium Real Estate Assets Located in Major Cities into AMTD Digital Inc. $FRZO -Forza X1 shares are trading higher amid continued volatility following Friday's IPO. $WMT -Walmart Q2 EPS $1.77 Down From $1.78 YoY, Sales $152.90B Beat $150.75B Estimate; Shares Gain. Walmart U.S. grew comp sales 6.5%, including mid-teens in food, and eCommerce up 12% $QUCY -Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE $BLND -Blend Labs Q2 EPS $(0.19), Inline, Sales $65.54M Beat $58.32M Estimate. Blend Labs Sees FY22 Consolidated Revenue $230M-$250M Vs $232.32M Est., Lowers Blend Platform Revenue Guidance From $140M-$150M To $135M-$145M, Raises Title365 Revenue Guidance From $90M-$100M To $95M-$105M
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 16 at 12:08 PM
$QUCY will keep an eye on it
0 · Reply
stockstelegraph
stockstelegraph Aug. 16 at 11:36 AM
Mainz Biomed B.V. $QUCY stock soared 13.85% to $10.52 in the pre-market trading.The company and Dante Genomics recently announced the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE).
0 · Reply